Reframing loss of efficacy in sacral neuromodulation: a neurofunctional service model for coloproctology Authors: E Ram, D Carter Published: 2026 ABSTRACT AbstractBackgroundSacral neuromodulation (SNM) is an established therapeutic option for fecal incontinence, low anterior resection syndrome (LARS), and selected bowel dysfunction phenotypes encountered in colorectal practice. Despite durable benefit in many patients, secondary loss of efficacy (LOE) remains a common long-term management problem and is often interpreted primarily through a mechanical lens.ObjectiveTo refine a conceptual neurofunctional service model for LOE in SNM and to translate it into a more clinically applicable framework for coloproctological practice.FrameworkFor the purposes of this paper, LOE is defined as deterioration after a previously effective phase, operationalized by one or more of the following: loss of at least 50% of the initial clinically meaningful benefit; deterioration of five or more points on a validated symptom instrument (Wexner Continence Score, LARS Score, or equivalent), or documented worsening in a structured patient symptom diary; or sustained patient-reported decline over at least two consecutive assessments, after exclusion of technical failure. We propose a structured pathway comprising confirmation of LOE, systematic technical exclusion, minimum neurofunctional reassessment, phenotype-guided reprogramming, predefined reassessment intervals, and explicit thresholds for revision or explantation. Terms such as neuroadaptive drift and phenotype mismatch are presented as explanatory hypotheses rather than established mechanisms.Clinical implicationsViewing SNM as a dynamic network-modulating therapy rather than a static device intervention may reduce unnecessary procedural escalation and improve the consistency of long-term management. The proposed model is intended as an implementable service framework for structured follow-up and reprogramming in patients with suspected LOE.Keywords: Sacral neuromodulation, Fecal incontinence, Low anterior resection syndrome, Selected constipation phenotypes, Pelvic floor disorders, Adaptive programming, Loss of efficacy Introduction Sacral neuromodulation has assumed an increasingly prominent role in colorectal surgical practice, with established indications including fecal incontinence (FI), low anterior resection syndrome (LARS), and carefully selected bowel dysfunction phenotypes. Long-term studies report clinically meaningful improvement in many patients; however, variability in therapeutic response and secondary loss of efficacy (LOE) remain important and incompletely resolved clinical challenges [1, 2, 3, 4, 27, 28]. Current frameworks for understanding SNM failure remain predominantly mechanical in orientation, focusing on lead migration, hardware malfunction, battery depletion, or suboptimal stimulation parameters [5, 6]. While technical causes must always be systematically excluded, this approach may oversimplify a more complex biological and clinical reality and may direct clinical resources toward hardware-based interventions when the dominant problem is functional rather than technical. Contemporary understanding of pelvic floor disorders has shifted toward integrated models of dysfunction involving sacral spinal circuits, supraspinal control centres, peripheral sensory pathways, autonomic regulation, and behavioural adaptation [7, 8]. Within such systems, therapeutic responses are dynamic and may evolve over time. In this paper, we argue that a clinically relevant subset of apparent SNM failure is better understood as functional deterioration occurring despite intact hardware. We therefore propose a neurofunctional service model for LOE that is intended not as proof of mechanism but as a practical framework for structured longitudinal management. This paper is informed by 17 years of clinical practice at a high-volume tertiary referral centre with a dedicated weekly SNM service and a structured longitudinal follow-up programme. Defining loss of efficacy in SNM For the purposes of this paper, LOE should be understood as deterioration after a previously effective therapeutic phase rather than simple non-response. A practical operational definition is required if a service model is to be clinically useful. We propose that LOE may be recorded when all of the following conditions are met: (1) the patient had a previously documented clinically meaningful benefit after SNM implantation or programming adjustment; (2) there is subsequent decline reflected by at least one of the following: loss of at least 50% of the initial benefit, deterioration of five or more points on a validated symptom instrument (Wexner Continence Score, LARS Score, or equivalent) relative to best achieved post-implantation baseline [24], or documented worsening in a structured patient symptom diary; or sustained patient-reported decline at two consecutive assessments; and (3) technical failure has not been identified on standard evaluation. This definition deliberately separates LOE from primary treatment failure and from isolated transient fluctuation. It also distinguishes technical LOE from functional LOE. Technical LOE refers to deterioration associated with demonstrable hardware or system abnormality. Functional LOE refers to deterioration despite acceptable technical parameters and should trigger structured reassessment before revision or explantation is considered. Sacral neuromodulation: mechanism beyond stimulation Sacral neuromodulation has historically been conceptualized as modulation of sacral reflex pathways, principally at the S3 level [9, 10]. However, experimental and clinical studies suggest that the effects of SNM extend beyond local spinal circuitry. Functional neuroimaging studies have demonstrated changes in cortical and subcortical activation during SNM, including the anterior cingulate cortex, thalamus, and insula, regions involved in sensory integration and interoceptive processing [11, 12]. Neurophysiological studies further suggest system-level effects on excitability and sensory processing [13]. These observations support the view that SNM may influence distributed control networks rather than acting solely as a local stimulator. In that context, continued benefit may depend not only on hardware integrity and parameter selection but also on the changing state of the neural and symptom phenotype being modulated [14, 15, 25, 26]. Neuroadaptive drift and phenotype mismatch: explanatory hypotheses Sustained electrical stimulation may be associated with time-dependent adaptation at multiple levels of the neuraxis, including changes in receptor behaviour, excitability, and network responsiveness [16, 17]. We use the term neuroadaptive drift as an explanatory hypothesis for progressive reduction in response to a previously effective stimulation paradigm despite preserved hardware. We use the term phenotype mismatch as a second explanatory hypothesis. Pelvic floor disorders are heterogeneous and may evolve over time [18, 19]. The dominant symptom driver at implantation may not remain the dominant driver years later. Comorbidity progression, altered sensory-motor balance, postoperative changes, or bowel habit evolution may produce a clinical picture that no longer aligns with the original programming strategy. These terms are intended as clinically useful hypotheses for interpretation and management, not as demonstrated mechanisms. Their purpose is to support a more disciplined reassessment process when patients present with apparent LOE. Scope of the model: bowel dysfunction and constipation The scope of this paper is deliberately centred on coloproctological SNM practice, especially FI [25], LARS, and selected bowel dysfunction phenotypes already encountered within established or evolving colorectal neuromodulation services. Constipation is not treated here as a single entity. Where constipation remains within scope, we refer only to selected phenotypes in which SNM may reasonably enter clinical discussion, specifically, carefully selected patients with slow-transit constipation in whom SNM has documented evidence; outlet obstruction and mixed outlet-obstructive phenotypes are explicitly excluded from this model. This paper does not propose a universal service model for all constipation phenotypes. Slow-transit constipation merits particular caution. Published long-term follow-up data suggest that effectiveness may be limited and phenotype-specific. The recently cited 5-year follow-up study of SNM in slow-transit constipation [29] is therefore relevant mainly as a reminder that constipation should be discussed narrowly and with phenotype specificity, rather than as a broad indication category. Institutional context: a national referral experience The present framework is grounded in long-term service experience at a tertiary referral pelvic floor unit with a dedicated weekly SNM clinic and structured longitudinal follow-up. The service receives patients for implantation, follow-up, reprogramming, and tertiary reassessment of suspected LOE. In this environment, a recurring pattern is the referral of patients labelled as hardware failures or revision candidates despite subsequently normal technical evaluation. In a proportion of such patients, structured reprogramming and phenotype reassessment restore clinically meaningful benefit, thereby avoiding immediate operative escalation. We present this institutional context to explain the clinical motivation for the proposed service model. These observations should not be interpreted as formal outcome data. Operationalizing the neurofunctional service model The model is intended as a structured pathway for clinical decision-making after suspected LOE. It is not a replacement for individualized judgement, but it does require explicit minimum steps if it is to be reproducible across services. Confirm and quantify LOE Confirm and quantify LOE The first step is to verify that the patient previously responded and that meaningful deterioration has now occurred. This should be documented using the original treatment target, current symptom burden, a validated score where available (e.g. Wexner score, LARS score, diary-based episode counts), and a structured patient report. A single subjective complaint without documented decline should not automatically trigger revision planning. Step 2:Systematic technical exclusion Systematic technical exclusion Technical exclusion should include impedance testing across available electrode configurations, battery status assessment, review of the active program, and radiographic evaluation when lead migration or fracture is suspected [5, 20]. Confirmed hardware failure should be managed according to standard device protocols and lies outside the functional branch of the algorithm. Step 3:Minimum neurofunctional reassessment Minimum neurofunctional reassessment When technical parameters are acceptable, a minimum structured reassessment should follow. We propose the following core elements: (1) current symptom phenotype and dominant complaint; (2) bowel pattern and defecatory phenotype; (3) medication review; (4) relevant comorbidity review, including pain amplification, autonomic symptoms, or psychological distress when clinically relevant; (5) review of anorectal physiology or pelvic floor testing when indicated; and (6) confirmation that the original treatment target remains appropriate. This step is intended to identify functional LOE and potential phenotype mismatch. Step 4:Structured reprogramming sequence Structured reprogramming sequence Reprogramming should be approached as a defined therapeutic phase rather than an ad hoc technical adjustment. A practical sequence is: first, reassess electrode configuration and active contact selection; second, optimize amplitude within tolerable sensory or subsensory limits as appropriate; third, adjust pulse width; fourth, adjust frequency and cycling pattern; and fifth, revisit phenotype–program alignment if the dominant symptom profile has changed. Each programming change should be recorded with its rationale and linked to the current symptom phenotype. Step 5:Reassessment intervals and success criteria Reassessment intervals and success criteria Reassessment should be longitudinal and predefined. A reasonable service model is early review within 2–6 weeks after a programming change, intermediate reassessment by 6–12 weeks, and a defined decision point by approximately 3–6 months. A successful reprogramming response may be defined pragmatically as restoration of at least 50% of the lost benefit, improvement in the relevant validated symptom score (five or more points on the Wexner or LARS score), or return to the previously accepted functional state. Step 6:Thresholds for revision or explantation Thresholds for revision or explantation Surgical revision or explantation should generally be reserved for one of the following situations: demonstrable technical abnormality; persistent clinically significant LOE despite a documented structured reprogramming sequence and reassessment interval; intolerable adverse effects; infection or other device-related complications; or a change in overall clinical context such that SNM no longer represents an appropriate therapy. In the absence of these conditions, immediate escalation to surgery risks unnecessary procedures and repeated therapeutic escalation (Fig. 1). Proposed neurofunctional algorithm for management of loss of efficacy in sacral neuromodulation. Suspected LOE → Step 1: Confirm previous response and quantify decline (validated symptom score; structured patient report) → Step 2: Systematic technical exclusion (impedance testing; battery status; radiographic evaluation when indicated). If technical abnormality confirmed: manage per standard device protocols. If hardware intact (Functional LOE): → Step 3: Minimum neurofunctional reassessment (symptom phenotyping; medication and comorbidity review; anorectal physiology when indicated) → Step 4: Structured reprogramming (electrode configuration → amplitude → pulse width → frequency/cycling; each change documented with rationale and phenotype alignment) → Step 5: Reassess at predefined intervals (2–6 weeks after each change; 6–12 weeks intermediate; decision point at 3–6 months; success defined as restoration of at least 50% of lost benefit). If clinically meaningful benefit restored: continue adaptive longitudinal follow-up. If clinically significant LOE persists after documented structured reprogramming: → Step 6: Consider surgical revision or device explantation per established criteria. Limitations Several limitations should be acknowledged. The proposed framework extrapolates from long-term clinical experience and the existing SNM literature rather than from contemporary prospective studies specifically designed to test LOE phenotyping or structured reprogramming pathways in colorectal neuromodulation populations; the evidence base for each component of the pathway therefore varies in quality and directness. Neuroadaptive drift and phenotype mismatch are presented here as explanatory hypotheses, not as prospectively validated mechanistic entities in SNM populations. Objective biomarkers capable of confirming these constructs in individual patients do not currently exist. The service framework proposed here has not been tested in randomized controlled trials. Current support for structured reprogramming in SNM-related LOE derives primarily from observational reports, clinical series, and expert practice patterns [21, 22]. The institutional perspective described reflects referral-centre experience and may overrepresent complex or refractory cases. This may influence the clinical framing of LOE and the perceived frequency of avoidable escalation. Finally, although the model is centred on colorectal practice, it may require modification for bladder-predominant SNM indications or other neuromodulation services. Clinical take-home points Loss of efficacy in SNM should not be reflexively attributed to device failure. Loss of efficacy in SNM should not be reflexively attributed to device failure. A practical definition of LOE is necessary for reproducible longitudinal care. A practical definition of LOE is necessary for reproducible longitudinal care. Technical exclusion must precede functional interpretation. Technical exclusion must precede functional interpretation. Neuroadaptive drift and phenotype mismatch are useful explanatory hypotheses, not proven mechanisms. Neuroadaptive drift and phenotype mismatch are useful explanatory hypotheses, not proven mechanisms. Structured, phenotype-guided reprogramming should constitute an active therapeutic phase. Structured, phenotype-guided reprogramming should constitute an active therapeutic phase. Revision or explantation should generally follow documented failure of structured reprogramming, not precede it. Revision or explantation should generally follow documented failure of structured reprogramming, not precede it. Constipation should remain within scope only for selected and clearly defined phenotypes. Constipation should remain within scope only for selected and clearly defined phenotypes. Conclusion Sacral neuromodulation remains a valuable component of colorectal practice, but secondary LOE is common and frequently understructured in clinical management. A neurofunctional service model does not deny the importance of technical causes. Rather, it creates a disciplined pathway in which technical exclusion is followed by formal reassessment, structured reprogramming, and explicit thresholds for procedural escalation. In this sense, the proposed framework is intended to move LOE management from a reactive device-focused approach toward a reproducible longitudinal service model. The framework described here reflects referral-centre practice and should be understood as a proposed specialist-centre model rather than a validated universal algorithm; adaptation will be required in centres with different programming resources, patient selection criteria, and multidisciplinary support. Prospective studies are now needed to validate the proposed operational definition of LOE, to test structured reprogramming pathways, and to identify markers that distinguish technical from functional deterioration more reliably. Author contributions E.R. conceived the concept and wrote the main manuscript text. All authors contributed to the clinical interpretation, critical revision of the manuscript, and approved the final version. Data availability No datasets were generated or analysed during the current study. Declarations Conflict of interest The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.